CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position

CorMedix reports $355M cash and reaffirms $325–345M 2026 revenue guidance, with higher 2027 reimbursement rates set.

What the company is saying

CorMedix Therapeutics is emphasizing its strong liquidity with unaudited cash and cash equivalents of approximately $355 million as of September 30, 2026. The company reaffirms its full-year 2026 revenue guidance of $325 million to $345 million, signaling confidence in its commercial execution. Management highlights the Centers for Medicare & Medicaid Services’ (CMS) final rule, which sets the Q1 2027 DefenCath post-TDAPA Add-on at $8.32 per dialysis session—3x to 5x higher than the current $2.37 rate for Q3 and Q4 2026. CorMedix distances itself from third-party projections about future Add-on rates, stating it has not provided utilization or pricing data to external parties and warning that such projections are highly uncertain. The company anticipates a decline in the Add-on rate in Q2 2027 compared to Q1, followed by increases in Q3 and/or Q4, but expects all 2027 quarters to exceed the current $2.37 rate, with the annual average more than doubling the current rate. The tone is measured, with explicit caveats about the uncertainty of future reimbursement calculations and a commitment to provide further details during the November 12, 2026, earnings call.

What the data suggests

The company’s unaudited cash position of $355 million as of September 30, 2026, indicates substantial liquidity. Revenue guidance for 2026 remains unchanged at $325 million to $345 million, suggesting management’s confidence in meeting previously stated targets. The CMS’s finalized Q1 2027 Add-on reimbursement rate for DefenCath of $8.32 per dialysis session is a material increase from the current $2.37, falling within the previously guided 3x–5x range. CorMedix’s own projections for 2027 Add-on rates are directional, not precise, but the company expects the average rate across all four quarters to be more than double the current rate, implying a favorable reimbursement environment. The company is transparent about the limitations of third-party projections, highlighting that actual Add-on rates will depend on CMS’s application of utilization data and that it has not shared internal data with external parties. No detailed breakdown of revenue, expenses, or profitability is provided, and all financials are unaudited at this stage. The data supports a narrative of improving reimbursement and stable financial footing, but leaves open questions about underlying profitability and operational leverage.

Analysis

The announcement is measured in tone, providing realised figures for cash ($355 million, unaudited) and reaffirmed revenue guidance ($325–345 million for 2026), as well as a concrete reimbursement rate for Q1 2027 ($8.32 per session) set by CMS. Forward-looking statements are present but are mostly limited to anticipated trends in Add-on rates for DefenCath in 2027, which are explicitly qualified as subject to CMS methodology and utilization data. The company is careful to distance itself from third-party projections, emphasizing uncertainty and not providing its own detailed forecasts beyond general directional statements. There is no evidence of exaggerated claims or narrative inflation; the language is factual and avoids promotional overreach. No large capital outlay or speculative long-term benefit is disclosed. The main gap is the absence of profitability metrics, which limits the signal to weak_positive under the Disclosure Completeness Rule.

Risk flags

• ●Reimbursement risk remains significant, as future Add-on rates for DefenCath beyond Q1 2027 will be recalculated quarterly by CMS and are subject to change based on utilization data and CMS methodology. This introduces uncertainty in forecasting revenue beyond the first quarter of 2027.
• ●The company’s financial disclosures are unaudited and limited to headline figures for cash and revenue guidance, with no detailed breakdown of operating expenses, margins, or net profitability. This restricts investors’ ability to assess underlying business performance and cash burn.
• ●CorMedix explicitly warns that third-party projections about future Add-on rates are unreliable due to the absence of shared utilization and pricing data. This highlights the risk that external expectations may diverge from actual outcomes, potentially leading to investor misinterpretation or disappointment if future rates do not match optimistic forecasts.

Bottom line

CorMedix enters the final quarter of 2026 with a robust cash position of $355 million and unchanged full-year revenue guidance of $325–345 million, underlining operational stability. The finalized $8.32 per session reimbursement rate for DefenCath in Q1 2027 represents a major uplift from the current $2.37, but future quarterly Add-on rates will be recalculated and remain uncertain, with the company projecting only that the annual average will exceed double the current rate. Management is careful to distance itself from external projections, emphasizing that actual future rates depend on CMS decisions and utilization patterns. Investors should focus on the November 12, 2026, earnings call for audited results and more granular financial detail. The most important takeaway is that near-term reimbursement is materially higher, but the sustainability of these rates and their impact on profitability will depend on future CMS determinations and internal execution.

Announcement summary

(NASDAQ:CRMD) CorMedix Therapeutics provided a business update ahead of its scheduled conference call on November 12, 2026, to discuss complete quarterly financial performance. As of September 30, 2026, CorMedix reported unaudited cash and cash equivalents of approximately $355 million. The company reaffirmed its August 2026 total revenue guidance for full-year 2026, projecting revenue between $325 million and $345 million. On October 28, 2026, the Centers for Medicare & Medicaid Services (CMS) released the 2027 End-Stage Renal Disease Prospective Payment System (ESRD PPS) final rule, which established a post-TDAPA Add-on for DefenCath (taurolidine and heparin) of $8.32 per dialysis session for the first quarter of 2027, and introduced a new quarterly process for calculating Add-On adjustments. The Q1 2027 Add-on of $8.32 is within CorMedix's previously guided range of 3x-5x higher than the current $2.37 Add-on in effect for Q3 and Q4 of 2026. CorMedix noted that a large dialysis organization (LDO) made statements about the quarterly trajectory of the 2027 DefenCath post-TDAPA Add-on payments following the CMS final rule, but CorMedix has not provided the LDO or any other party with past or forecasted utilization or pricing data necessary to estimate future quarterly adjustments. The company stated that any third-party projections regarding future quarterly adjustments are subject to significant uncertainty without access to relevant utilization and pricing data, and such projections should not be interpreted as guidance from CorMedix. Based on its evaluation of sales data and contractual arrangements, CorMedix anticipates the DefenCath Add-on will decline in Q2 2027 compared to Q1, but increase in Q3 and/or Q4 2027 compared to Q2, depending on how CMS applies certain utilization data. CorMedix believes the Add-on rate for all four quarters in 2027 will exceed the current rate of $2.37, and that the average Add-on rate for all four quarters in 2027 will be more than 2x the current rate of $2.37. The company expects to provide more specifics about its third quarter earnings call approximately one week prior to the scheduled meeting.

Disagree with this article?